{"id":12479,"date":"2026-05-28T19:00:00","date_gmt":"2026-05-28T17:00:00","guid":{"rendered":"http:\/\/stocks-future.com\/?guid=bc319de276901f1a4beb4280a7898585"},"modified":"2026-05-28T19:00:00","modified_gmt":"2026-05-28T17:00:00","slug":"evecxia-therapeutics-publishes-article-on-50-years-of-clinical-evidence-underpinning-evx-101-as-an-adjunctive-therapy-for-psychiatric-diseases","status":"publish","type":"post","link":"https:\/\/stocks-future.com\/?p=12479","title":{"rendered":"Evecxia Therapeutics Publishes Article on 50 Years of Clinical Evidence Underpinning EVX-101 as an Adjunctive Therapy for Psychiatric Diseases"},"content":{"rendered":"<p>\n<i>Multi-pronged clinical evidence supports that Serotonin Synthesis Amplification can augment serotonin reuptake inhibitor (e.g., SSRI) therapeutic efficacy, safely<\/i><\/p><br\/><a href=\"https:\/\/mms.businesswire.com\/media\/20260527557514\/en\/2815577\/5\/Logo_March_2018.jpg\"><img src=\"https:\/\/mms.businesswire.com\/media\/20260527557514\/en\/2815577\/22\/Logo_March_2018.jpg\" \/><\/a><br\/><a href=\"https:\/\/mms.businesswire.com\/media\/20260527557514\/en\/2815577\/5\/Logo_March_2018.jpg\"><img src=\"https:\/\/mms.businesswire.com\/media\/20260527557514\/en\/2815577\/21\/Logo_March_2018.jpg\" \/><\/a><p>\n<i>EVX-101 is a first-in-class Serotonin Synthesis Amplification antidepressant drug candidate<\/i><\/p><p>\n<i>Historically, a clinical evidence foundation risk-mitigates psychiatric drug clinical development<\/i><\/p><p>RESEARCH TRIANGLE PARK, N.C.--(BUSINESS WIRE)--Evecxia Therapeutics, Inc.\u2014a clinical-stage neuroscience company developing a novel class of Serotonin Synthesis Amplification therapies\u2014today announced the publication of the peer-reviewed article titled \u201c<i>Serotonin Synthesis Amplification to Augment the Therapeutic Efficacy of Serotonin Reuptake Inhibitor Antidepressants - Five Decades of Clinical Evidence<\/i>\u201d in the Journal of Clinical Psychopharmacology. The review article was co-authored with Dr. Stefania Chaikali, MD, MS, of the Department of Psychiatry, Massachusetts General Hospital, Harvard Medical School, and is freely available via open access (<a  href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=https%3A%2F%2Fjournals.lww.com%2Fpsychopharmacology%2Ffulltext%2F9900%2Fserotonin_synthesis_amplification_to_augment_the.544.aspx&amp;esheet=54542234&amp;newsitemid=20260527557514&amp;lan=en-US&amp;anchor=LINK&amp;index=1&amp;md5=ee350fd6cf978533eb5d1dad26146cb5\" rel=\"nofollow\" shape=\"rect\">LINK<\/a>).<\/p><p>\n<b>Key Findings of the Article<\/b><\/p><ul class=\"bwlistdisc\">\n<li>\nSerotonin reuptake inhibitors (e.g., SSRIs) appear to elevate human forebrain serotonin activity only modestly, which could be causal of their modest therapeutic efficacy.<\/li>\n<li>\nAdjunctive Serotonin Synthesis Amplification can elevate forebrain serotonin activity beyond the serotonin reuptake inhibitor effect.<\/li>\n<li>\nIn clinical trials, Serotonin Synthesis Amplification therapy has shown encouraging antidepressant augmentation efficacy, with promising safety; but previous pharmacological approaches had limitations precluding clinical implementation.<\/li>\n<li>\nNo FDA-approved antidepressant employs a Serotonin Synthesis Amplification pharmacology \u2013 Evecxia\u2019s EVX-101 would be the first.<\/li>\n<\/ul><p>\n\u201cDiscovering novel psychiatric drugs is difficult, as animal models of psychiatric disease fail to predict human therapeutic efficacy,\u201d said Jacob Jacobsen, PhD, Chief Executive Officer and Co-founder of Evecxia Therapeutics. \u201cEVX-101 is supported by multipronged clinical evidence, which historically risk-mitigates Phase 2\/3 development in psychiatry. Indeed, 100% of FDA-approved psychiatric drugs are founded in primary clinical evidence.\u201d<\/p><p>\n<b>About EVX-101<\/b><\/p><p>\nEVX-101 is an oral, gastro-retentive, sustained-release tablet formulation of 5-HTP (the natural immediate precursor to serotonin) and low-dose carbidopa (multiplies 5-HTP\u2019s bioavailability). EVX-101 is designed to produce sufficient and sustained 5-HTP plasma levels, resulting in sufficient and sustained Serotonin Synthesis Amplification, elevation of serotonin activity beyond the SSRI effect, and augmentation of SSRI efficacy. In Phase 1 clinical studies, EVX-101, as adjunctive to SSRI therapy, transformed 5-HTP\u2019s pharmacokinetic (PK) profile and demonstrated evidence of elevation of forebrain serotonin activity beyond the SSRI effect - with a favorable safety and tolerability profile.<\/p><p>\n<b>About Evecxia Therapeutics<\/b><\/p><p>\nEvecxia is the first Company dedicated to realizing the therapeutic potential of Serotonin Synthesis Amplification\u2014building a stronger, more resilient brain serotonin system\u2014to treat psychiatric indications. Evecxia\u2019s lead candidate <b>EVX-101<\/b> is being developed as next-line oral adjunctive (add-on) therapy for obsessive-compulsive disorder (OCD) and depression patients for whom monotherapy with first-line serotonin reuptake inhibitor antidepressants (e.g., SSRIs such as Prozac\u00ae) yields inadequate therapeutic relief.<\/p><br\/> <b>Contacts<\/b> <br\/><p>\nJacob Jacobsen, PhD, CEO\n<br\/>Evecxia Therapeutics, Inc.\n<br\/><a  href=\"mailto:info@evecxia.com\" rel=\"nofollow\" shape=\"rect\">info@evecxia.com<\/a><\/p>","protected":false},"excerpt":{"rendered":"<p>Multi-pronged clinical evidence supports that Serotonin Synthesis Amplification can augment serotonin reuptake inhibitor (e.g., SSRI) therapeutic efficacy, safely<br \/>\nEVX-101 is a first-in-class Serotonin Synthesis Amplification antidepressant drug candid&#8230;<\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[1],"tags":[],"class_list":["post-12479","post","type-post","status-publish","format-standard","hentry","category-infos-businesswire"],"_links":{"self":[{"href":"https:\/\/stocks-future.com\/index.php?rest_route=\/wp\/v2\/posts\/12479","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/stocks-future.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/stocks-future.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/stocks-future.com\/index.php?rest_route=\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/stocks-future.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=12479"}],"version-history":[{"count":1,"href":"https:\/\/stocks-future.com\/index.php?rest_route=\/wp\/v2\/posts\/12479\/revisions"}],"predecessor-version":[{"id":12480,"href":"https:\/\/stocks-future.com\/index.php?rest_route=\/wp\/v2\/posts\/12479\/revisions\/12480"}],"wp:attachment":[{"href":"https:\/\/stocks-future.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=12479"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/stocks-future.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=12479"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/stocks-future.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=12479"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}